Irene A Burger1, Debra A Goldman2, Hebert Alberto Vargas3, Michael W Kattan4, Changhon Yu4, Lei Kou4, Vaagn Andikyan5, Dennis S Chi5, Hedvig Hricak3, Evis Sala3. 1. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA; Department of Radiology and Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland. Electronic address: Irene.burger@usz.ch. 2. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA. 3. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA. 4. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. 5. Department of Gynecology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Abstract
PURPOSE: The use of multivariable clinical models to assess postoperative prognosis in ovarian cancer increased. All published models incorporate surgical debulking. However, postoperative CT can detect residual disease (CT-RD) in 40% of optimally resected patients. The aim of our study was to investigate the added value of incorporating CT-RD evaluation into clinical models for assessment of overall survival (OS) and progression free survival (PFS) in patients after primary cytoreductive surgery (PCS). METHODS: 212 women with PCS for advanced ovarian cancer between 01/1997 and 12/2011, and a contrast enhanced abdominal CT 1-7 weeks after surgery were included in this IRB approved retrospective study. Two radiologists blinded to clinical data, evaluated all CT for the presence of CT-RD, and Cohen's kappa assessed agreement. Cox proportional hazards regression with stepwise selection was used to develop OS and PFS models, with CT-RD incorporated afterwards. Model fit was assessed with bootstrapped Concordance Probability Estimates (CPE), accounting for over-fitting bias by correcting the initial estimate after repeated subsampling. RESULTS: Readers agreed on the majority of cases (179/212, k=0.68). For OS and PFS, CT-RD was significant after adjusting for clinical factors with a CPE 0.663 (p=0.0264) and 0.649 (p=0.0008). CT-RD was detected in 37% of patients assessed as optimally debulked (RD<1cm) and increased the risk of death (HR: 1.58, 95% CI: 1.06-2.37%). CONCLUSION: CT-RD is a significant predictor after adjusting for clinical factors for both OS and PFS. Incorporating CT-RD into the clinical model improved the prediction of OS and PFS in patients after PCS for advanced ovarian cancer.
PURPOSE: The use of multivariable clinical models to assess postoperative prognosis in ovarian cancer increased. All published models incorporate surgical debulking. However, postoperative CT can detect residual disease (CT-RD) in 40% of optimally resected patients. The aim of our study was to investigate the added value of incorporating CT-RD evaluation into clinical models for assessment of overall survival (OS) and progression free survival (PFS) in patients after primary cytoreductive surgery (PCS). METHODS: 212 women with PCS for advanced ovarian cancer between 01/1997 and 12/2011, and a contrast enhanced abdominal CT 1-7 weeks after surgery were included in this IRB approved retrospective study. Two radiologists blinded to clinical data, evaluated all CT for the presence of CT-RD, and Cohen's kappa assessed agreement. Cox proportional hazards regression with stepwise selection was used to develop OS and PFS models, with CT-RD incorporated afterwards. Model fit was assessed with bootstrapped Concordance Probability Estimates (CPE), accounting for over-fitting bias by correcting the initial estimate after repeated subsampling. RESULTS: Readers agreed on the majority of cases (179/212, k=0.68). For OS and PFS, CT-RD was significant after adjusting for clinical factors with a CPE 0.663 (p=0.0264) and 0.649 (p=0.0008). CT-RD was detected in 37% of patients assessed as optimally debulked (RD<1cm) and increased the risk of death (HR: 1.58, 95% CI: 1.06-2.37%). CONCLUSION: CT-RD is a significant predictor after adjusting for clinical factors for both OS and PFS. Incorporating CT-RD into the clinical model improved the prediction of OS and PFS in patients after PCS for advanced ovarian cancer.
Authors: Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Evis Sala; Lorenzo Mannelli; Kenji Yamamoto; Michelle Griffin; Nyree Griffin; Lee Grant; Richard Parker; Robin Crawford Journal: Int J Gynecol Cancer Date: 2011-02 Impact factor: 3.437
Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Michael J Sundborg; G Scott Rose; Peter G Rose; Stephen C Rubin; Franco Muggia; William P McGuire Journal: J Clin Oncol Date: 2007-11-19 Impact factor: 44.544
Authors: Dennis S Chi; Pedro T Ramirez; Jerrold B Teitcher; Svetlana Mironov; Debra M Sarasohn; Revathy B Iyer; Eric L Eisenhauer; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Carol L Brown; Carol Aghajanian; David M Gershenson; William J Hoskins; Hedvig Hricak; Richard R Barakat Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Ramez N Eskander; James Kauderer; Krishnansu S Tewari; Robert S Mannel; Robert E Bristow; David M O'Malley; Stephen C Rubin; Gretchen E Glaser; Chad A Hamilton; Keiichi Fujiwara; Warner K Huh; Frederick Ueland; Jean-Marie Stephan; Robert A Burger Journal: Gynecol Oncol Date: 2018-03-15 Impact factor: 5.482